U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07182149) titled 'A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors' on Sept. 11.
Brief Summary: This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
HNSCC
ESCC
Esophageal Adenocarcinoma
Gastric Adenocarcinoma
GEJ Adenocarcinoma
Ovarian Cancer
NSCLC
Cervical Cancer
Endometrial Cancer
Intervention:
DRUG: NRM-823
NRM-823 is a bispecific T-Cell Engager
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Normunity AccelCo, Inc.
Published by HT Digital Co...